Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate.

Autor: Simpson JB; Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sekela JJ; Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Graboski AL; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Borlandelli VB; Department of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands., Bivins MM; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Barker NK; UNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sorgen AA; Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA., Mordant AL; UNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Johnson RL; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Bhatt AP; Division of Gastroenterology and Hepatology, Department of Medicine, Center for Gastrointestinal Biology and Disease, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Fodor AA; Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, USA., Herring LE; UNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Overkleeft H; Department of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands., Lee JR; Department of Medicine, Division of Nephrology and Hypertension, New York, New York, USA., Redinbo MR; Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Biochemistry and Biophysics, Department of Microbiology and Immunology, and the Institute for Biological and Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jazyk: angličtina
Zdroj: Gut microbes [Gut Microbes] 2022 Jan-Dec; Vol. 14 (1), pp. 2107289.
DOI: 10.1080/19490976.2022.2107289
Abstrakt: Mycophenolate mofetil (MMF) is an important immunosuppressant prodrug prescribed to prevent organ transplant rejection and to treat autoimmune diseases. MMF usage, however, is limited by severe gastrointestinal toxicity that is observed in approximately 45% of MMF recipients. The active form of the drug, mycophenolic acid (MPA), undergoes extensive enterohepatic recirculation by bacterial β-glucuronidase (GUS) enzymes, which reactivate MPA from mycophenolate glucuronide (MPAG) within the gastrointestinal tract. GUS enzymes demonstrate distinct substrate preferences based on their structural features, and gut microbial GUS enzymes that reactivate MPA have not been identified. Here, we compare the fecal microbiomes of transplant recipients receiving MMF to healthy individuals using shotgun metagenomic sequencing. We find that neither microbial composition nor the presence of specific structural classes of GUS genes are sufficient to explain the differences in MPA reactivation measured between fecal samples from the two cohorts. We next employed a GUS-specific activity-based chemical probe and targeted metaproteomics to identify and quantify the GUS proteins present in the human fecal samples. The identification of specific GUS enzymes was improved by using the metagenomics data collected from the fecal samples. We found that the presence of GUS enzymes that bind the flavin mononucleotide (FMN) is significantly correlated with efficient MPA reactivation. Furthermore, structural analysis identified motifs unique to these FMN-binding GUS enzymes that provide molecular support for their ability to process this drug glucuronide. These results indicate that FMN-binding GUS enzymes may be responsible for reactivation of MPA and could be a driving force behind MPA-induced GI toxicity.
Databáze: MEDLINE